{"pmid":32330545,"title":"African American COVID-19 Mortality: A Sentinel Event.","text":["African American COVID-19 Mortality: A Sentinel Event.","J Am Coll Cardiol","Ferdinand, Keith C","Nasser, Samar A","32330545"],"journal":"J Am Coll Cardiol","authors":["Ferdinand, Keith C","Nasser, Samar A"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330545","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jacc.2020.04.040","keywords":["covid-19","cardiovascular disease","coronavirus","disparity","hypertension"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["African American"],"_version_":1664996914863538176,"score":8.518259,"similar":[{"pmid":32293639,"title":"COVID-19 and African Americans.","text":["COVID-19 and African Americans.","JAMA","Yancy, Clyde W","32293639"],"journal":"JAMA","authors":["Yancy, Clyde W"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293639","week":"202016|Apr 13 - Apr 19","doi":"10.1001/jama.2020.6548","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["African Americans"],"_version_":1664636192524599296,"score":92.73743},{"pmid":32306369,"title":"The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities.","text":["The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities.","The Coronavirus disease 2019 (COVID-19) pandemic has significantly impacted and devastated the world. As the infection spreads, the projected mortality and economic devastation are unprecedented. In particular, racial and ethnic minorities may be at a particular disadvantage as many already assume the status of a marginalized group. Black Americans have a long-standing history of disadvantage and are in a vulnerable position to experience the impact of this crisis and the myth of Black immunity to COVID-19 is detrimental to promoting and maintaining preventative measures. We are the first to present the earliest available data in the peer-reviewed literature on the racial and ethnic distribution of COVID-19-confirmed cases and fatalities in the state of Connecticut. We also seek to explode the myth of Black immunity to the virus. Finally, we call for a National Commission on COVID-19 Racial and Ethnic Health Disparities to further explore and respond to the unique challenges that the crisis presents for Black and Brown communities.","J Racial Ethn Health Disparities","Laurencin, Cato T","McClinton, Aneesah","32306369"],"abstract":["The Coronavirus disease 2019 (COVID-19) pandemic has significantly impacted and devastated the world. As the infection spreads, the projected mortality and economic devastation are unprecedented. In particular, racial and ethnic minorities may be at a particular disadvantage as many already assume the status of a marginalized group. Black Americans have a long-standing history of disadvantage and are in a vulnerable position to experience the impact of this crisis and the myth of Black immunity to COVID-19 is detrimental to promoting and maintaining preventative measures. We are the first to present the earliest available data in the peer-reviewed literature on the racial and ethnic distribution of COVID-19-confirmed cases and fatalities in the state of Connecticut. We also seek to explode the myth of Black immunity to the virus. Finally, we call for a National Commission on COVID-19 Racial and Ethnic Health Disparities to further explore and respond to the unique challenges that the crisis presents for Black and Brown communities."],"journal":"J Racial Ethn Health Disparities","authors":["Laurencin, Cato T","McClinton, Aneesah"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32306369","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s40615-020-00756-0","keywords":["covid-19","coronavirus","disparity","ethnicity","pandemic","race"],"source":"PubMed","weight":0,"locations":["Americans","Connecticut"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664641855738871808,"score":78.24548},{"pmid":32181680,"title":"The Role of the American Heart Association in the Global COVID-19 Pandemic.","text":["The Role of the American Heart Association in the Global COVID-19 Pandemic.","Circulation","Elkind, Mitchell S V","Harrington, Robert A","Benjamin, Ivor J","32181680"],"journal":"Circulation","authors":["Elkind, Mitchell S V","Harrington, Robert A","Benjamin, Ivor J"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181680","week":"202012|Mar 16 - Mar 22","doi":"10.1161/CIRCULATIONAHA.120.046749","keywords":["coronavirus infections","epidemiology","heart failure","hypertension","life expectancy","pandemics","social determinants of disease"],"source":"PubMed","topics":["General Info"],"weight":1,"_version_":1664640874586308609,"score":76.80469},{"pmid":32215613,"title":"Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for Epidemiologic Investigations.","text":["Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for Epidemiologic Investigations.","Mortality from coronavirus disease 2019 (COVID-19) is strongly associated with cardiovascular disease, diabetes, and hypertension. These disorders share underlying pathophysiology related to the renin-angiotensin system (RAS) that may be clinically insightful. In particular, activity of the angiotensin-converting enzyme 2 (ACE2) is dysregulated in cardiovascular disease, and this enzyme is used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to initiate the infection. Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart. Conversely, mechanistic evidence from related coronaviruses suggests that SARS-CoV-2 infection may downregulate ACE2, leading to toxic overaccumulation of Angiotensin II that induces acute respiratory distress syndrome and fulminant myocarditis. RAS inhibition could mitigate this effect. With conflicting mechanistic evidence, we propose key clinical research priorities necessary to clarify the role of RAS inhibition in COVID-19 mortality that could be rapidly addressed by the international research community.","Clin Infect Dis","Hanff, Thomas C","Harhay, Michael O","Brown, Tyler S","Cohen, Jordana B","Mohareb, Amir M","32215613"],"abstract":["Mortality from coronavirus disease 2019 (COVID-19) is strongly associated with cardiovascular disease, diabetes, and hypertension. These disorders share underlying pathophysiology related to the renin-angiotensin system (RAS) that may be clinically insightful. In particular, activity of the angiotensin-converting enzyme 2 (ACE2) is dysregulated in cardiovascular disease, and this enzyme is used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to initiate the infection. Cardiovascular disease and pharmacologic RAS inhibition both increase ACE2 levels, which may increase the virulence of SARS-CoV-2 within the lung and heart. Conversely, mechanistic evidence from related coronaviruses suggests that SARS-CoV-2 infection may downregulate ACE2, leading to toxic overaccumulation of Angiotensin II that induces acute respiratory distress syndrome and fulminant myocarditis. RAS inhibition could mitigate this effect. With conflicting mechanistic evidence, we propose key clinical research priorities necessary to clarify the role of RAS inhibition in COVID-19 mortality that could be rapidly addressed by the international research community."],"journal":"Clin Infect Dis","authors":["Hanff, Thomas C","Harhay, Michael O","Brown, Tyler S","Cohen, Jordana B","Mohareb, Amir M"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32215613","week":"202013|Mar 23 - Mar 29","doi":"10.1093/cid/ciaa329","keywords":["angiotensin-converting enzyme 2","covid-19","cardiovascular disease","renin-angiotensin system","sars-cov-2"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664638838245425152,"score":66.997734},{"pmid":32292919,"pmcid":"PMC7151392","title":"The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer.","text":["The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer.","JACC CardioOncol","Ganatra, Sarju","Hammond, Sarah P","Nohria, Anju","32292919"],"journal":"JACC CardioOncol","authors":["Ganatra, Sarju","Hammond, Sarah P","Nohria, Anju"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292919","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaccao.2020.03.001","keywords":["ace-2, angiotensin-converting enzyme 2","acei, angiotensin converting enzyme inhibitor","arb, angiotensin receptor blocker","cdc, centers for disease control","covid-19","cvd, cardiovascular disease","coronavirus","coronavirus disease 2019, covid-19","mers-cov, middle east respiratory syndrome coronavirus","sars-cov-2","sars-cov-2, severe acute respiratory syndrome coronavirus 2","who, world health organization","cancer","cardio-oncology","cardiovascular disease"],"source":"PubMed","topics":["Treatment","Mechanism","Diagnosis","Prevention"],"weight":1,"_version_":1664636192483704832,"score":56.879436}]}